Boston Scientific Co. (NYSE:BSX) Stock Holdings Decreased by Great Lakes Retirement Inc.

Great Lakes Retirement Inc. decreased its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,018 shares of the medical equipment provider’s stock after selling 301 shares during the quarter. Great Lakes Retirement Inc.’s holdings in Boston Scientific were worth $2,056,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Boston Scientific by 32.4% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,786 shares of the medical equipment provider’s stock worth $317,000 after buying an additional 927 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Boston Scientific during the third quarter worth $89,000. Grove Bank & Trust lifted its stake in Boston Scientific by 12.9% during the third quarter. Grove Bank & Trust now owns 2,801 shares of the medical equipment provider’s stock worth $235,000 after purchasing an additional 320 shares during the last quarter. Creative Planning boosted its holdings in Boston Scientific by 7.7% in the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock worth $17,113,000 after purchasing an additional 14,663 shares during the period. Finally, Boomfish Wealth Group LLC bought a new stake in Boston Scientific during the third quarter valued at $281,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $106.03 on Wednesday. The firm has a market capitalization of $156.26 billion, a PE ratio of 84.82, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 12 month low of $64.54 and a 12 month high of $107.17. The company’s 50 day simple moving average is $95.19 and its 200 day simple moving average is $87.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the transaction, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 53,830 shares of company stock valued at $5,149,969. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Friday, January 10th. Barclays raised their target price on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Monday. Piper Sandler upped their target price on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. raised their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Finally, Canaccord Genuity Group upped their price objective on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.